Trial Profile
Planned phase III trial of inhaled liposomal amikacin (ARIKAYCE) in patients with non-tuberculous mycobacteria (NTM) lung infections
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 22 Sep 2014
Price :
$35
*
At a glance
- Drugs Amikacin (Primary)
- Indications Nontuberculous mycobacterium infections; Respiratory tract infections
- Focus Registrational; Therapeutic Use
- Sponsors Insmed
- 22 Sep 2014 New trial record
- 04 Aug 2014 According to an Insmed media release, the company will proceed with this second Phase 3 study which will be designed to confirm, in as short a timeframe as possible, the positive culture conversion results seen in the Phase 2 study and results are expected in 2017.